Divested.
EyeD Pharma is developing micro-implants for drug release over a prolonged period of time.
Indigo is developing an implantable sensor that allows to continuously measure glucose and other metabolites for up to two years.
Helping clinicians make faster, smarter decisions with AI-powered alerts for patient deterioration.
